ANI Pharmaceuticals bids SEK 5.6 billion for Egetis at 27% premium with 42% of holders committed
GlobeNewswire via BioSpace · · AI-summarised by FinFlash
US drugmaker ANI Pharmaceuticals offered SEK 11.25 a share for Sweden's Egetis Therapeutics, a 27% premium to the 60-day average price, valuing it at about SEK 5.6 billion or roughly $560 million. Egetis's board unanimously backs the deal and holders of about 42% have agreed to accept. The offer needs 90% acceptance and regulatory approvals, with an acceptance period expected from about November 20 to December 18. EMCITATE sales could peak above $300 million.
So What?
The bid highlights continued appetite for rare-disease assets among smaller US pharma groups. ANI's debt-funded deal adds leverage, so watch its Q3 call today.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.